rs1131691686
Variant summary
Our verdict is Pathogenic. Variant got 17 ACMG points: 17P and 0B. PM2PM5PP2PP3_StrongPP5_Very_Strong
The NM_000020.3(ACVRL1):c.1135G>A(p.Glu379Lys) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000000684 in 1,461,612 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. E379D) has been classified as Likely pathogenic.
Frequency
Consequence
NM_000020.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 17 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ACVRL1 | NM_000020.3 | c.1135G>A | p.Glu379Lys | missense_variant | 8/10 | ENST00000388922.9 | NP_000011.2 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD3 exomes AF: 0.00000796 AC: 2AN: 251236Hom.: 0 AF XY: 0.00000736 AC XY: 1AN XY: 135802
GnomAD4 exome AF: 6.84e-7 AC: 1AN: 1461612Hom.: 0 Cov.: 31 AF XY: 0.00000138 AC XY: 1AN XY: 727060
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Telangiectasia, hereditary hemorrhagic, type 2 Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Nov 09, 2023 | The ACVRL1 c.1135G>A; p.Glu379Lys variant (rs1131691686) has been reported in multiple unrelated individuals diagnosed with hereditary hemorrhagic telangiectasia (Brakensiek 2008, Fontalba 2008, Kuehl 2005, Lenato 2006, Lesca 2004, Nishida 2012). In functional assays, this variant exhibits a decreased BMP9 response and inability to properly localize to the cell surface (Alaa El Din 2015). This variant is reported in the ClinVar database (Variation ID: 429940), and it is found on only two chromosomes (2/251236 alleles) in the Genome Aggregation Database, indicating it is not a common polymorphism. The glutamic acid at codon 379 is a highly conserved residue in the protein kinase domain, computational analyses predict that this variant is deleterious (REVEL: 0.969). Based on the above information, this variant is considered pathogenic. References: Alaa El Din F et al. Functional and splicing defect analysis of 23 ACVRL1 mutations in a cohort of patients affected by Hereditary Hemorrhagic Telangiectasia. PLoS One. 2015 Jul 15;10(7):e0132111. Brakensiek K et al. Detection of a significant association between mutations in the ACVRL1 gene and hepatic involvement in German patients with hereditary haemorrhagic telangiectasia. Clin Genet. 2008 Aug;74(2):171-7. Fontalba A et al. Mutation study of Spanish patients with hereditary hemorrhagic telangiectasia. BMC Med Genet. 2008 Aug 1;9:75. Kuehl HK et al. Hepatic manifestation is associated with ALK1 in hereditary hemorrhagic telangiectasia: identification of five novel ALK1 and one novel ENG mutations. Hum Mutat. 2005 Mar;25(3):320. Lenato GM et al. DHPLC-based mutation analysis of ENG and ALK-1 genes in HHT Italian population. Hum Mutat. 2006 Feb;27(2):213-4. Lesca G et al. Molecular screening of ALK1/ACVRL1 and ENG genes in hereditary hemorrhagic telangiectasia in France. Hum Mutat. 2004 Apr;23(4):289-99. Nishida T et al. Brain arteriovenous malformations associated with hereditary hemorrhagic telangiectasia: gene-phenotype correlations. Am J Med Genet A. 2012 Nov;158A(11):2829-34. - |
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, University of Leipzig Medical Center | Jul 18, 2018 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 27, 2024 | This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 379 of the ACVRL1 protein (p.Glu379Lys). This variant is present in population databases (no rsID available, gnomAD 0.003%). This missense change has been observed in individuals with hereditary hemorrhagic telangiectasia (PMID: 15024723, 15712270, 16429404, 18498373, 22991266, 24603890). ClinVar contains an entry for this variant (Variation ID: 429940). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ACVRL1 protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects ACVRL1 function (PMID: 26176610). For these reasons, this variant has been classified as Pathogenic. - |
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Clinical Genetics Laboratory, Skane University Hospital Lund | May 27, 2022 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jun 06, 2024 | Not observed at significant frequency in large population cohorts (gnomAD); Published functional studies suggest that p.(E379K) has a negative impact on ACVRL1 receptor activity and protein maturation (PMID: 26176610); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 18498373, 15879500, 15266205, 22991266, 18673552, 17384219, 15712270, 15521985, 15024723, 26176610, 30578397, 32503579, 32300199, 16429404, 23535011, 34966542) - |
Pathogenic, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Jun 22, 2023 | PP3, PM2_supporting, PS3, PS4 - |
Hereditary hemorrhagic telangiectasia Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Apr 12, 2024 | The p.Glu379Lys variant in ACVRL1 has been reported in >5 individuals with hereditary hemorrhagic telangiectasia (HHT; Lesca 2004 PMID: 15024723, Kuehl 2005 PMID: 15712270, Lenato 2006 PMID: 16429404). It has also been identified in 0.001% (1/69794) of South Asian chromosomes by gnomAD (http://gnomad.broadinstitute.org) and has been reported in ClinVar (Variation ID 429940). Computational prediction tools and conservation analyses support that this variant may impact the protein. In vitro functional studies provide some evidence that this variant impacts protein function (Alaa El Din 2015 PMID: 26176610); however, these types of assays may not accurately represent biological function. Additionally, the number of ACVRL1 missense variants in the general population is lower than expected (Z=3.18, https://gnomad.broadinstitute.org/gene/ENSG00000139567), providing some evidence that this variant may not be tolerated. In summary, although additional studies are required to fully establish its clinical significance, this variant meets criteria to be classified as likely pathogenic for autosomal dominant HHT. ACMG/AMP Criteria applied: PS4, PP2, PP3, PM2_supporting, PS3_supporting. - |
Cardiovascular phenotype Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Apr 27, 2021 | The p.E379K pathogenic mutation (also known as c.1135G>A), located in coding exon 7 of the ACVRL1 gene, results from a G to A substitution at nucleotide position 1135. The glutamic acid at codon 379 is replaced by lysine, an amino acid with similar properties. This mutation has been reported in several individuals with hereditary hemorrhagic telangiectasia (HHT) from multiple research groups. The first report of p.E379K was in a French individual with a probable diagnosis of HHT (Lesca G et al. Hum. Mutat., 2004 Apr;23:289-99). This mutation was also reported in three unrelated Italian individuals meeting Curacao diagnostic criteria. Familial co-segregation of p.E379K and HHT was reportedly observed in two of the three aforementioned individuals (Lenato GM et al. Hum. Mutat., 2006 Feb;27:213-4). More recently, this mutation was reported in two individuals with a clinical diagnosis of HHT by Curacao diagnostic criteria (Zhao Y et al. Mol Genet Genomic Med, 2019 09;7:e893). In a separate study, this mutation has also been reported in a pulmonary arterial hypertension (PAH) cohort (Wang XJ et al. Eur Respir J, 2019 03;53:). In addition, in vitro functional studies demonstrated that the resulting protein is predominantly immature and not localized to the cell surface (Alaa El Din F et al. PLoS ONE, 2015 Jul;10:e0132111). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at